e-Drug3D

2059

FUTIBATINIB

INN
FUTIBATINIB

cas 1448169-71-8

CLASS

ANTINEOPLASTIC
FGFR2 1, 2 AND 3 KINASE COVALENT INHIBITOR (IC50 VALUES OF LESS THAN 4 NANOMOLAR)
TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA

ROUTE (list)

ORAL

ATC code

L01EN04

PK parameters

Tmax 2 HOUR
VD 66 LITER
Cl 20 LITER / HOUR
PPB 95 PERCENT
t1/2 2.9 HOUR

Solubility

INSOLUBLE IN WATER

Target

TARGET FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)
FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1)
FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3)

PDB
7D5O (C-SRC IN COMPLEX WITH TAS-120)

Download experimental 3D coordinates of TZ0 with added hydrogens

Fibroblast growth factor receptor 1 UNIPROT P11362 FGFR1

Download SDF file

2-Propen-1-one, 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]- (ACI)

Formula:
C22H22N6O3

Calculated chemical properties:

MW 418.46
NB_atoms 31
XLogP 1.78
PSA 102.122
NB_HD 2
NB_HA 9
fsp3 0.27
Lipinski(0=no;1=yes) 1

FDA
NDA 214801 (label) INN (FUTIBATINIB) LYTGOBI (TAIHO ONCOLOGY) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY